These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 15522262

  • 1. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y, Blomme EA, Waring JF.
    Chem Biol Interact; 2004 Nov 01; 150(1):71-85. PubMed ID: 15522262
    [Abstract] [Full Text] [Related]

  • 2. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA, Sagartz JE, Morris DL.
    Nat Rev Drug Discov; 2007 Aug 01; 6(8):636-49. PubMed ID: 17643090
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The promise of toxicogenomics.
    Waring JF, Halbert DN.
    Curr Opin Mol Ther; 2002 Jun 01; 4(3):229-35. PubMed ID: 12139308
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Toxicogenomics in biomarker discovery.
    Decristofaro MF, Daniels KK.
    Methods Mol Biol; 2008 Jun 01; 460():185-94. PubMed ID: 18449488
    [Abstract] [Full Text] [Related]

  • 9. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A, Suter L, Ruepp S, Singer T, Weiser T, Albertini S.
    Mutat Res; 2005 Aug 04; 575(1-2):102-15. PubMed ID: 15924886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P, Sasaki J.
    Mutat Res; 2010 Dec 04; 705(3):165-71. PubMed ID: 20466069
    [Abstract] [Full Text] [Related]

  • 12. Application of toxicogenomics to drug development.
    Lakkis MM, DeCristofaro MF, Ahr HJ, Mansfield TA.
    Expert Rev Mol Diagn; 2002 Jul 04; 2(4):337-45. PubMed ID: 12138498
    [Abstract] [Full Text] [Related]

  • 13. The importance of applying toxicogenomics to increase the efficiency of drug discovery.
    Barros SA.
    Pharmacogenomics; 2005 Sep 04; 6(6):547-50. PubMed ID: 16142994
    [No Abstract] [Full Text] [Related]

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 04; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 15. Predictive toxicogenomics in preclinical discovery.
    Barros SA, Martin RB.
    Methods Mol Biol; 2008 Dec 04; 460():89-112. PubMed ID: 18449484
    [Abstract] [Full Text] [Related]

  • 16. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J.
    Arzneimittelforschung; 2004 Dec 04; 54(5):251-8. PubMed ID: 15212186
    [Abstract] [Full Text] [Related]

  • 17. Current status and future prospects of toxicogenomics in drug discovery.
    Khan SR, Baghdasarian A, Fahlman RP, Michail K, Siraki AG.
    Drug Discov Today; 2014 May 04; 19(5):562-78. PubMed ID: 24216320
    [Abstract] [Full Text] [Related]

  • 18. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives.
    Leighton JK.
    Int J Toxicol; 2005 May 04; 24(3):153-5. PubMed ID: 16040567
    [Abstract] [Full Text] [Related]

  • 19. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A.
    Toxicol Lett; 2009 Apr 10; 186(1):32-5. PubMed ID: 18809476
    [Abstract] [Full Text] [Related]

  • 20. The next innovation cycle in toxicogenomics: environmental epigenetics.
    Reamon-Buettner SM, Mutschler V, Borlak J.
    Mutat Res; 2008 Apr 10; 659(1-2):158-65. PubMed ID: 18342568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.